Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Similares en SciELO
Compartir
Revista médica del Hospital General de México
versión On-line ISSN 2524-177Xversión impresa ISSN 0185-1063
Resumen
VIDAL-GONZALEZ, David; URIBE, Misael; MONTALVO-JAVE, Eduardo E. y NUNO-LAMBARRI, Natalia. Assessment of non-alcoholic fatty liver disease by non-invasive methods: present and future perspectives. Rev. med. Hosp. Gen. Méx. [online]. 2020, vol.83, n.3, pp.135-143. Epub 06-Sep-2021. ISSN 2524-177X. https://doi.org/10.24875/hgmx.20000088.
The difficulties that exist to assess the non-alcoholic fatty liver disease (NAFLD) prevalence and diagnosis are due to the absence of signs and symptoms in the early stages, as well as the low sensitivity of liver enzymes to identify the disease and the need to request a liver biopsy as reference standard for diagnosis despite its limitations. Non-invasive methods depend on different approaches, such as imaging techniques, including ultrasound, transient elastography, computed tomography, and magnetic resonance imaging (MRI), which can detect simple hepatic steatosis but cannot distinguish non-alcoholic steatohepatitis. Furthermore, there are biomarkers that differentiated the spectrum of the disease; these include acute phase proteins, cytokines, apoptosis, and oxidative stress markers. As well as a variety of miRNAs, which are expressed in NAFLD and could be used as blood biomarkers of progressive liver damage.
Palabras llave : Biomarkers; Liver damage; Non-invasive methods; Steatosis.